Sildenafil for pulmonary hypertension in neonates
Referencias
Additional references
Abrams D, Schulze‐Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000;84:E4.
Adatia I. Recent advances in pulmonary vascular disease. Current Opinion in Pediatrics 2002;14:292‐7.
Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. The Cochrane Database of Systematic Reviews 2001, Issue 4.
Behn D, Potter MJ. Sildenafil‐mediated reduction in retinal function in heterozygous mice lacking the gamma‐subunit of phosphodiesterase. Investigative Ophthalmology and Visual Science 2001;42:523‐7.
Burton AJ, Reynolds A, O'Neill D. Sildenafil (Viagra) a cause of proliferative diabetic retinopathy?. Eye 2000;14:785‐6. [MEDLINE: 16]
Carroll WD, Dhillon R. Sildenafil as a treatment for pulmonary hypertension. Archives of Disease of Childhood 2003;88:827‐8. [MEDLINE: 19]
Dukarm RC, Morin FC, Rusell JA, Steinhorn RH. Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension. Pediatric Research 1998;44:831‐7.
Erickson S, Reyes J, Bohn D, Adatia I. Sildenafil (Viagra) in childhood and neonatal pulmonary hypertension. Journal of the American College of Cardiology (suppl)2002; Vol. 39:402A.
Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. The Cochrane Database of Systematic Reviews 2001, Issue 2.
Gersony WM. Neonatal pulmonary hypertension: pathophysiology, classification, and etiology. Clinics in Perinatology 1984;11:517‐24.
Goldman AP, Tasker RC, Haworth SG, Sigston PE, Macrae DJ. Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996;98:706‐13.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. New England Journal of Medicine 2004;351:1425‐36.
Ichinose F, Erana‐Garcia J, Hromi J, Raveh Y, Jones R, Krim L, Clark MW, Winkler JD, Bloch KD, Zapol WM. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Critical Care Medicine 2001;29:1000‐5.
Ikeda D, Tsujino I, Ohira H, Itoh N, Kamigaki M, Ishimaru S, Sakaue S, Nishimura M. Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. Journal of Cardiovascular Pharmacology 2005;45:286‐9.
Kanthapillai P, Lasserson T, Walters E. Sildenafil for pulmonary hypertension. The Cochrane Database of Systematic Reviews 2004, Issue 4.
Kinsella JP, Abman SH. Inhaled nitric oxide: current and future uses in neonates. Seminars in Perinatology 2000;24:387‐95.
Kumar S. Indian doctor in protest after using Viagra to save "blue babies". British Medical Journal 2002;325:181. [MEDLINE: 5]
Lewin S. Viagra neonatal experimentation ‐ the Pandora's box!. Indian Pediatrics 2002;39:894‐5.
Marsh CS, Marden B, Newsom R. Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension. British Journal of Ophthalmology 2004;88:306‐7. [MEDLINE: 2]
Oliver J, Webb DJ. Sildenafil for "blue babies". Such unlicensed drug use might be justified as last resort. British Medical Journal 2002;325:1174.
Patole S, Travadi J. Sildenafil for "blue babies". Ethics, conscience, and science have to be balanced against limited resources. British Medical Journal 2002;325:1174.
Pierce CM, Petros AJ, Fielder AR. No evidence for severe retinopathy of prematurity following sildenafil. British Journal of Ophthalmology 2005;89:250.
Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. American Journal of Physiology 1994;266:L536‐43.
Roberts JD, Fineman JR, Morin FC, Shaul PW, Rimar S, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. New England Journal of Medicine 1997;336:605‐10.
Sastry BKS, Narasimhan C, Reddy K, Raju S. Clinical efficacy of sildenafil in primary pulmonary hypertension. Journal of the American College of Cardiology 2004;43:1149‐53.
Shah PS, Hellmann J, Adatia I. Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn. Journal of Perinatal Medicine 2004;32:168‐70.
Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2002;165:1098‐102.
Shekerdemian LS, Ravn HB, Penny DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatric Research 2004;55:413‐8.
Subhedar NV, Jauhari P, Natarajan R. Cost of inhaled nitric oxide therapy in neonates. Lancet 2002;359:1781‐2.
Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatric Pulmonology 2003;36:529‐35.
Walsh‐Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105:14‐20.
Wessel DL, Adatia I, Van Marter LJ, Thompson JE, Kane JW, Stark AR, Kourembanas S. Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1997;100:e7.
